TL;DR
This study delves into the diverse roles of extracellular vesicles (EVs) originating from skeletal muscle, revealing distinct functional subpopulations (large EVs and small EVs) with unique molecular compositions and biological effects. Understanding this heterogeneity is crucial for developing precise EV-based diagnostics and therapeutics for regenerative medicine.
What Problem Does This Paper Address?
Extracellular vesicles (EVs) are increasingly recognized for their potential in disease diagnostics and therapeutics due to their ability to carry bioactive cargo between cells. However, the complex nature of EVs, particularly those derived from tissues in vivo, means their full functional diversity remains largely unexplored. Most research has focused on EVs from cell cultures, which may not accurately reflect the in vivo environment. This paper aims to bridge this gap by investigating the functional heterogeneity of endogenous EVs directly from skeletal muscle, a major tissue with significant roles in metabolism and homeostasis. The challenge lies in dissecting these complex tissue-derived EV populations into distinct functional subsets and understanding their specific contributions to cellular communication and tissue regulation.
Methods
The researchers employed a multi-omics approach to characterize and understand the functional differences between EV subpopulations. Key techniques included:
- Isolation of EV subpopulations: Optimized differential ultracentrifugation was used to isolate "large EVs" (L-EVs, size > 150 nm) and "small EVs" (S-EVs, size < 100 nm) from mouse skeletal muscle tissue.
- Transmission Electron Microscopy (TEM): Used to visualize the morphology of the isolated EVs and confirm their vesicular nature.
- Proteomic Analysis (LC-MS/MS): Liquid chromatography coupled with tandem mass spectrometry was employed to identify and quantify proteins within the L-EV and S-EV subpopulations, revealing distinct composition signatures.
- Bioinformatic Analysis: Gene Ontology (GO) and KEGG pathway enrichment analyses were used to infer the subcellular origins and biological functions of proteins identified in the EVs.
- Cellular Assays:
- Cellular Uptake Assay: Memglow-labeled EVs were used to assess the uptake efficiency of L-EVs and S-EVs by myoblasts and endothelial cells (ECs).
- RNA Sequencing (RNA-seq): Used to analyze global gene expression changes in myoblasts and ECs treated with L-EVs or S-EVs, identifying differentially expressed genes (DEGs).
- Cell Proliferation Assay (CCK-8): Measured the impact of EVs on cell proliferation.
- Quantitative Real-time Polymerase Chain Reaction (qPCR): Used to validate the expression of specific genes (e.g., mitochondrial genes, differentiation markers).
- Cell Migration Assay: Assessed the effect of EVs on myoblast migration.
- LC-MS/MS-based Targeted Metabolomics: Analyzed the changes in intracellular metabolite profiles in myoblasts treated with EVs.
Datasets
The study utilized a public single-cell atlas of mouse skeletal muscle for mapping the proteomic data of tissue-EVs to their cell origins.
Key Insights and Ideas
- Skeletal Muscle EVs are Heterogeneous: The study definitively shows that skeletal muscle tissue releases distinct subpopulations of EVs (L-EVs and S-EVs) with unique molecular profiles and functional roles.
- Functional Specialization: L-EVs are enriched with mitochondrial proteins involved in metabolic regulation, while S-EVs are enriched with muscle cell-specific proteins related to muscle function regulation.
- Differential Cellular Interactions: S-EVs exhibit higher surface protein abundance and cell uptake rates compared to L-EVs, suggesting distinct mechanisms for interacting with recipient cells.
- Targeted Therapeutic Potential: The distinct properties of S-EVs (biomarker potential) and L-EVs (metabolic intervention) highlight their potential for tailored therapeutic applications.
Key Results
- Compositional Differences: Proteomic analysis identified 2128 proteins in tissue-EVs, with clear separation between L-EVs and S-EVs. L-EVs were enriched in mitochondrial proteins (e.g., HSPD1, GOT2, STOML2, MDH2), while S-EVs were enriched in tetraspanins (e.g., CD63, CD81, CD9, CD82).
- Subcellular Origins: S-EVs showed higher levels of cytoplasmic, cytomembrane, and nucleus proteins, whereas L-EVs were enriched in mitochondrial, cytoplasm, and ECM proteins.
- Mitochondrial Enrichment in L-EVs: Approximately 25.64% of EV proteins were mitochondrial, with L-EVs showing increased levels of MOM, matrix, and MIM proteins, implicating them in energy metabolism and redox pathways.
- Muscle-Specific Proteins in S-EVs: S-EVs were enriched in proteins related to muscle contraction, muscle development, cytoskeleton organization, and cell motility.
- Surface Protein Differences: S-EVs expressed higher levels of CD proteins and GPI-anchored proteins compared to L-EVs.
- Differential Cellular Uptake: S-EVs demonstrated higher uptake rates in both myoblasts and ECs compared to L-EVs.
- Distinct Biological Responses:
- Myoblasts: S-EV treatment led to increased cell migration, proliferation, and expression of differentiation markers (Myf5, myogenin). L-EV treatment primarily influenced mitochondrial-related gene expression and metabolic pathways (e.g., purine metabolism).
- Endothelial Cells (ECs): L-EVs induced changes in mitochondrial dynamics, enhancing fusion and potentially increasing energy production. S-EVs showed a trend towards increased ribosome density, suggesting a role in cell proliferation.
Limitations and Future Work
- Size-Based Subpopulation Separation: The study separated EVs based on size (L-EVs and S-EVs), acknowledging potential overlap between populations and the limitations of this classification method compared to biogenesis-based definitions.
- In Vitro vs. In Vivo: While the study uses tissue-derived EVs, the functional responses were primarily assessed in vitro using myoblasts and ECs. Future work should focus on validating these findings in vivo.
- Understanding Biogenesis: The exact mechanisms by which muscle tissue cell-derived mitochondrial proteins are sorted into L-EVs remain unclear, warranting further investigation into EV biogenesis routes.
- Clinical Translation: While the study highlights potential applications for S-EVs (biomarkers) and L-EVs (therapeutics), further research is needed to optimize their selection, specificity, and sensitivity for clinical use. Evaluating tissue selection and retention in vivo is also crucial.
Summary updated